Ischemic Preconditioning in Osteoarthritis and Back Pain
Launched by UNIVERSITY OF ILLINOIS AT CHICAGO · Jun 2, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a technique called ischemic preconditioning, which involves temporarily restricting blood flow to one thigh, for 50 minutes every other day over two weeks. The goal is to see if this method can help improve function and reduce pain in individuals suffering from knee osteoarthritis and low back pain. Researchers believe that by limiting blood flow, they may trigger the body to adapt and heal better, potentially leading to less pain and improved mobility.
To participate in this study, individuals need to be at least 50 years old and have reported knee pain and back pain that meets certain criteria. Participants should also be able to walk for at least 3 minutes without assistance and be able to give their written consent to join the trial. However, some people may not be eligible, including those who have had joint replacements, recent steroid injections, or certain medical conditions. If someone qualifies and decides to participate, they can expect to attend sessions where they will undergo the blood flow restriction treatment, and they will be closely monitored throughout the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Reported Knee Pain using ACR Criteria
- • Reported Back Pain using ODI Criteria \> 12
- • Ability to walk for at least 3 minutes without the use of aids
- • Ability to provide written informed consent
- Exclusion Criteria:
- • Younger than 50 years old
- • History of Knee or Hip Replacements
- • History of steroid injection within the previous 6 months
- • Presence of neuromuscular joint condition that affects lower extremity function
- • History of blood clots in the leg or any condition in which compression of the thigh is contraindicated
- • History of heart failure or thrombosis
- • Allergic to ultrasound gel
- • History of spine surgery
- • Non-English speaker
- • Currently pregnant or intends to become pregnant during the study
About University Of Illinois At Chicago
The University of Illinois at Chicago (UIC) is a leading academic institution renowned for its commitment to advancing health sciences through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, UIC harnesses the expertise of its diverse faculty and state-of-the-art facilities to conduct cutting-edge clinical studies aimed at improving patient outcomes. The university's robust infrastructure for clinical research, combined with its dedication to ethical standards and regulatory compliance, positions UIC as a pivotal contributor to the development of new treatments and therapies in various medical fields. Through strategic partnerships and community engagement, UIC strives to translate research findings into real-world applications, enhancing the health and well-being of populations locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Lindsay Hannigan
Principal Investigator
University of Illinois at Chicago
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported